Eupatilin
Based on 8 publication(s) in Google Scholar
Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.
For research use only. We do not sell to patients.
- Purity: 99.23%
- CAS No.: 22368-21-4
- Formula: C18H16O7
- Molecular Weight:344.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Oxygen Sensing Compound Library
HY-L045
-
Medicine Food Homology Compound Library
HY-L055
-
Pyroptosis Compound Library
HY-L059
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Flavonoids Library
HY-L068
-
Transcription Factor-Targeted Library
HY-L090
-
Lipid Metabolism Compound Library
HY-L091
-
Food-Sourced Compound Library
HY-L094
-
Anti-Cancer Natural Product Library
HY-L107
-
Antidepressant Compound Library
HY-L108
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Nuclear Receptor Compound Library
HY-L126
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
FDA-Approved Traditional Chinese Medicine Active Compound Library
HY-L163
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Tibetan Medicine Compound Library
HY-L191
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Eupatilin
More- Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]
- Int J Mol Med. 2021 Feb;47(2):511-522. [Abstract]
- Life Sci. 2020 Jul 15;253:117745. [Abstract]
- iScience. 2025 Oct 1;28(11):113687. [Abstract]
- J Inflamm Res. 2023 Mar 10:16:1027-1042. [Abstract]
- Animals (Basel). 2024 Jan 30;14(3):449. [Abstract]
- SSRN. 2023 Jul 3.
- Oxid Med Cell Longev. 2022 Jan 17:2022:1090034. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
ELISA
-
WB
-
IF
Biological Activity
|
PPARα |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: 6
|
Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 27400887] |
| AGS | IC50 |
0.5 x 10-4 M
Compound: Eupatilin
|
Antiproliferative activity against human AGS cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
Antiproliferative activity against human AGS cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
|
[PMID: 31784199] |
| Bcap37 | IC50 |
>100 μM
Compound: 6
|
Cytotoxicity against human Bcap37 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human Bcap37 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 27400887] |
| HepG2 | IC50 |
52.65 μM
Compound: 6
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 27400887] |
| MCF7 | IC50 |
90.07 μM
Compound: 6
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 27400887] |
| MKN-1 | IC50 |
0.5 x 10-4 M
Compound: Eupatilin
|
Antiproliferative activity against human MKN1 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
Antiproliferative activity against human MKN1 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
|
[PMID: 31784199] |
| SNU-638 | IC50 |
0.5 x 10-4 M
Compound: Eupatilin
|
Antiproliferative activity against human SNU638 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
Antiproliferative activity against human SNU638 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
|
[PMID: 31784199] |
| T-cell | IC50 |
11.7 μM
Compound: 16
|
Immunosuppressant activity in human T lymphocytes assessed as inhibition of anti-human CD3 and anti-human CD28 monoclonal antibody-induced T lymphocyte proliferation incubated for 72 hrs by FACS analysis
Immunosuppressant activity in human T lymphocytes assessed as inhibition of anti-human CD3 and anti-human CD28 monoclonal antibody-induced T lymphocyte proliferation incubated for 72 hrs by FACS analysis
|
[PMID: 31181920] |
| U-251 | IC50 |
>100 μM
Compound: 6
|
Cytotoxicity against human U251 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human U251 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 27400887] |
Eupatilin is a PPARα agonist. Eupatilin (10, 30, 100 μM) suppresses IL-4 expression and degranulation in RBL-2H3 cells[1]. Eupatilin (50-100 μM) slightly reduces cell viability of HaCaT cells. Eupatilin (10, 30, 50, 100 μM) increases PPARα transactivation and expression in HaCaT cells. Eupatilin (10, 30, 50 μM) also suppresses TNFα-induced MMP-2/-9 expression in HaCaT cells. Furthermore, Eupatilin inhibits TNFα-induced p65 translocation, IκBα Phosphorylation, AP-1 and MAPK signaling via PPARα[2]. Eupatilin (10-50 μM) shows no cytotoxic effects on ARPE19 cells. Eupatilin (10, 25, 50 μM) elevates cell viability from oxidative stress, and inhibits H2O2-induced ROS production in ARPE19 cells. Moreover, Eupatilin (50 μM) inbibits H2O2-induced cells apoptosis and promotes the activation of PI3K/Akt pathway in RPE cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 22368-21-4
-
Appearance Solid
-
Molecular Weight 344.32
-
Formula C18H16O7
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(C2=CC=C(OC)C(OC)=C2)OC3=CC(O)=C(OC)C(O)=C13
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]2021 Jan;11(1):143-155. PMID: 33532186 -
Int J Mol Med
Formononetin protects against cisplatin‑induced acute kidney injury through activation of the PPARα/Nrf2/HO‑1/NQO1 pathway. [Abstract]2021 Feb;47(2):511-522. PMID: 33416097 -
Life Sci
Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model. [Abstract]2020 Jul 15;253:117745. PMID: 32376269 -
iScience
Eupatilin ameliorates spinal cord injury by inhibiting damage-associated microglia and optimizing the regenerative microenvironment. [Abstract]2025 Oct 1;28(11):113687. PMID: 41146716 -
J Inflamm Res
Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway. [Abstract]2023 Mar 10:16:1027-1042. PMID: 36926276
Eupatilin purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2023 Mar 10:16:1027-1042. [Abstract]
The cell viability after treatment with different concentrations (0,1.25,2.5,5,10,20,40,80,160 μM) of Eupatilin for 24 hours.
Eupatilin purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2023 Mar 10:16:1027-1042. [Abstract]
The differences in TNF-α, IL-1β and IL-6, and TF mRNA expression were determined by RT-qPCR treated with Eupatilin (Eup) (10 μM).
Eupatilin purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2023 Mar 10:16:1027-1042. [Abstract]
The concentrations of TNF-α, IL-1β and IL-6 in RAW264.7 cell supernatants were detected by ELISA treated with Eupatilin (Eup) (10 μM).
Eupatilin purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2023 Mar 10:16:1027-1042. [Abstract]
The protein expression of TNF-α, IL-1β and IL-6, and TF were analyzed by Western blot. Eupatilin (Eup) (10 μM) was applied to RAW264.7 cells for 2 hours, followed by a 6-hour stimulation with LPS (1 μg/mL).
Eupatilin purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2023 Mar 10:16:1027-1042. [Abstract]
p-STAT3 (green) fluorescence images of RAW264.7 cells were captured under a confocal laser microscope treated with Eupatilin (Eup) (10 μM).
-
Animals (Basel)
Supplementation with Eupatilin during In Vitro Maturation Improves Porcine Oocyte Developmental Competence by Regulating Oxidative Stress and Endoplasmic Reticulum Stress. [Abstract]2024 Jan 30;14(3):449. PMID: 38338092 -
-
Oxid Med Cell Longev
Novel Application of Eupatilin for Effectively Attenuating Cisplatin-Induced Auditory Hair Cell Death via Mitochondrial Apoptosis Pathway. [Abstract]2022 Jan 17:2022:1090034. PMID: 35082962
Solvent & Solubility
DMSO : 33.33 mg/mL (96.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 1 mg/mL (2.90 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cell viability is detected using a MTT assay. In brief, after treatment, the medium is replaced with fresh medium containing 0.5 mg/mL MTT for 4 h at 37°C. Then, the medium is gently aspirated and 150 μL of DMSO is added to each well to solubilize the formazan crystals. The absorbance is measured at 450 nm by a microplate reader. The relative cell viability is defined as the absorbance of treated wells divided by that of the control[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Six-week-old female Balb/c mice are housed under conditions of controlled temperature (23 ± 2 °C), humidity (55 ± 5%), and 12 h light/dark cycles (06:00-18:00 h light, 18:00-06:00 dark). Briefly, Balb/c mice are sensitized on day −7 by a single application of 20 μL of 1.0% oxazolone in a mixture of acetone and olive oil (4:1) to the inner and outer surface of both ears. On day 0, the mouse ears are challenged with 20 μL of 0.1% oxazolone at 2-day intervals for 4 weeks post-sensitization. The mice are treated with the indicated concentrations of Eupatilin (1.5% or 3.0%) twice a day for 4 weeks. The control group is treated with vehicle alone (acetone and olive oil [4:1]). After 3 weeks, the mice are sacrificed and samples are collected. Ears are stored at −80 °C for RNA isolation and analysis or immediately fixed in 4% formalin for histological analysis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jung Y, et al. Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice. Biochem Biophys Res Commun. 2018 Feb 5;496(2):508-514. [Content Brief]
[2]. Jung Y, et al. Eupatilin with PPARα agonistic effects inhibits TNFα-induced MMP signaling in HaCaT cells. Biochem Biophys Res Commun. 2017 Nov 4;493(1):220-226. [Content Brief]
[3]. Du L, et al. Eupatilin prevents H2O2-induced oxidative stress and apoptosis in human retinal pigment epithelial cells. Biomed Pharmacother. 2017 Jan;85:136-140. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | 72.6069 mL |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | 14.5214 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL | 7.2607 mL | |
| 15 mM | 0.1936 mL | 0.9681 mL | 1.9362 mL | 4.8405 mL | |
| 20 mM | 0.1452 mL | 0.7261 mL | 1.4521 mL | 3.6303 mL | |
| 25 mM | 0.1162 mL | 0.5809 mL | 1.1617 mL | 2.9043 mL | |
| 30 mM | 0.0968 mL | 0.4840 mL | 0.9681 mL | 2.4202 mL | |
| 40 mM | 0.0726 mL | 0.3630 mL | 0.7261 mL | 1.8152 mL | |
| 50 mM | 0.0581 mL | 0.2904 mL | 0.5809 mL | 1.4521 mL | |
| 60 mM | 0.0484 mL | 0.2420 mL | 0.4840 mL | 1.2101 mL | |
| 80 mM | 0.0363 mL | 0.1815 mL | 0.3630 mL | 0.9076 mL |
Eupatilin Related Classifications
HY-N0783 Related Classifications
Powered by Bioz